AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20808204
Drug: Prednisone (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (1.5 mg/kg per day for 2 weeks then 0.75 mg/kg per day for 2 weeks)
Trial: 15639724
Drug: First line
RxNorm normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line therapy with carboplatin and paclitaxel
Trial: 15639724
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or more cycles of therapy
Trial: 15639724
Drug: Four or
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four or more cycles of therapy
Trial: 14592237
Drug: Physiological dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological dose of melatonin (0.14 mg)
Trial: 14592237
Drug: Supraphysiological dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiological dose of melatonin (2.2 mg)
Trial: 9988788
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (estradiol valerate 2 mg/day)
Trial: 9988788
Drug: Cyclic estrogen/sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic estrogen/sequential progestogen regimen
Trial: 31000133
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg)
Trial: 23149928
Drug: Hydroxybupropion concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxybupropion concentrations (per μg/ml)
Trial: 23149928
Drug: Bupropion dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion dosing to achieve hydroxybupropion level of 0.7 μg/ml
Trial: 12071235
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (40 mg)
Trial: 8909084
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with aftercare orientation and treatment contract
Trial: 17242632
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg/d) for 7 days starting 1 week after surgery
Trial: 15342900
Drug: Betamethasone (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (12 mg, 2 doses, intramuscular injection, 24 hours apart)
Trial: 11434939
Drug: Bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.03% twice daily (BID)
Trial: 11434939
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% twice daily (BID)
Trial: 32949
Drug: Lorazepam, Hyoscine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam, Hyoscine butylbromide, Ispaghula husk (all three agents)
Trial: 32949
Drug: One or
RxNorm normalized name: Geone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or two of the potent preparations (Lorazepam, Hyoscine butylbromide, Ispaghula husk)
Trial: 19864187
Drug: Implementation intention
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Implementation intention intervention (self‐administered questionnaire)
Trial: 24959775
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no drugs)
Trial: 15369509
Drug: Treatment interruption
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment interruption or poor adherence
Trial: 11275026
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy
Trial: 25986647
Drug: Buprenorphine maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine maintenance treatment (BMT) with 12-step meeting attendance
Trial: 20102058
Drug: Niphedipine (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niphedipine (calcium channel blocker)
Trial: 14982362
Drug: Mini-implants (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-implants (both miniplates and freestanding miniscrews)
Trial: 14982362
Drug: Nonkeratinized mucosa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonkeratinized mucosa surrounding implants
Trial: 9284739
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day alendronate (A5)
Trial: 9284739
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day alendronate (A10)
Trial: 3942084
Drug: Riboflavin supplementation
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin supplementation (0.3 mg/day)
Trial: 26186951
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of solifenacin 5 mg and trospium 5 mg with tamsulosin 0.4 mg for 2 months
Trial: 26186951
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg only
Trial: 22192849
Drug: Liquid, aluminum-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid, aluminum-adjuvanted V710 (30 μg)
Trial: 22192849
Drug: Liquid, non-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid, non-adjuvanted V710 (30 μg)
Trial: 22192849
Drug: Non-adjuvanted lyophilized
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted lyophilized V710 (60 μg)
Trial: 9477005
Drug: Midazolam (6.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (6.1 mg)
Trial: 8688987
Drug: Chlorphenamine (CPA)
RxNorm normalized name: chlorphenoxamine
DrugBank: Chlorphenoxamine (DB09007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorphenamine (CPA) regular release tablet (Histop) 4 mg
Trial: 2203322
Drug: Placebo (cellulose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose, twice daily for 16 weeks)
Trial: 9860106
Drug: Flunitrazepam 4
RxNorm normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 4 mg
Trial: 23289920
Drug: Single-dose nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose nitazoxanide (1,000 mg)
Trial: 24448936
Drug: Single-dose albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose albendazole (400 mg)
Trial: 23289920
Drug: Nitazoxanide-albendazole combination
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide-albendazole combination (1,000 mg-400 mg)
Trial: 19822704
Drug: Urtoxazumab (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urtoxazumab (0.1 to 3.0 mg/kg in healthy adults; 1.0 and 3.0 mg/kg in pediatric patients)
Trial: 7955800
Drug: Tirilazad mesylate
RxNorm normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate (1.5 mg/kg as 10-minute intravenous infusions every 6 hours for 21 doses)
Trial: 3118401
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA, 750 mg)
Trial: 10803924
Drug: TOR20 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOR20 (20 mg daily)
Trial: 10803924
Drug: TOR40 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOR40 (40 mg daily)
Trial: 14692654
Drug: TOR60 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOR60 (60 mg daily)
Trial: 8615961
Drug: Chemotherapy, Surgery,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy, Surgery, and Radiotherapy (C/S/XRT)
Trial: 8615961
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and Radiotherapy (C/XRT)
Trial: 25011946
Drug: Exenatide (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10-20 µg/day)
Trial: 25011946
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (thrice-daily, titrated to premeal glucose of 5.6-6.0 mmol/L)
Trial: 20424250
Drug: B-vitamin therapy
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin therapy (folic acid 2.5 mg/d, vitamin B(6) 25 mg/d, vitamin B(12) 1 mg/d)
Trial: 20424250
Drug: B-vitamin therapy
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin therapy
Trial: 17414234
Drug: Olanzapine (14.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (14.2 mg/day)
Trial: 17414234
Drug: Haloperidol (8.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (8.5 mg/day)
Trial: 12920661
Drug: Insulatard insulin
RxNorm normalized name: insulin isophane, human Injectable Suspension [Human Insulatard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulatard insulin
Trial: 8812025
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control group (40 children)
Trial: 30267620
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg/week for 12 weeks)
Trial: 21875635
Drug: AS03B-adjuvanted split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03B-adjuvanted split virion H1N1 vaccine
Trial: 14748815
Drug: Cocktail of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocktail of all probe drugs
Trial: 11109306
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mHD, nontreated by CC).
Trial: 1309691
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (36 mg daily subcutaneous injection)
Trial: 6329405
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg oral tablets
Trial: 6329405
Drug: Clotrimazole 100
RxNorm normalized name: clotrimazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 100 mg vaginal tablets and 1% cream
Trial: 7572582
Drug: Mibefradil 50
RxNorm normalized name: mibefradil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil 50 mg
Trial: 23901061
Drug: m-CIMT +
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-CIMT + IT (intensive therapy)
Trial: 20635633
Drug: Low-dose beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose beta-carotene supplementation (1.2 mg daily for six months) + Antihelminthic therapy (400 mg albendazole, two doses)
Trial: 20635633
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for beta-carotene + Placebo for antihelminthic therapy
Trial: 10322755
Drug: Local produced
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local produced plasma-derived hepatitis B vaccine
Trial: 7707121
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg clodronate
Trial: 2757911
Drug: Vigabatrin (GVG)
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigabatrin (GVG) 1-3 g day-1 for 7 weeks
Trial: 2757911
Drug: Long-term GVG
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term GVG therapy (2-4 g day-1) for a mean follow-up of 24 months
Trial: 31326681
Drug: Complete revascularization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete revascularization (staged PCI of all suitable non-culprit lesions plus optimal medical therapy)
Trial: 10694834
Drug: Cortisol 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol 80 mg/day for 5 days
Trial: 8222032
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.75 mg.kg‐1 30 min before separation from parents
Trial: 3776445
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (4 mg) started peroperatively
Trial: 3776445
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (4 mg) started postoperatively
Trial: 30224199
Drug: TIV (full-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIV (full-dose trivalent inactivated influenza vaccine)
Trial: 17582403
Drug: Tailfirst sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailfirst sperm injection
Trial: 10197663
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (neither medication)
Trial: 2181103
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of theophylline and doxapram
Trial: 29174079
Drug: Surfactant administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant administered through a laryngeal mask airway (LMA)
Trial: 22659190
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 30 mg/m² and carboplatin AUC 5 plus bevacizumab 10 mg/kg
Trial: 24721447
Drug: Microbicide gel
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbicide gel use
Trial: 7051564
Drug: Indomethacin, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 75 mg daily for 8.5 months (6-13 months)
Trial: 22381065
Drug: Self-help manual
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-help manual in addition to standard care and treatment
Trial: 22339984
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care and treatment
Trial: 19576338
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers at both admission and discharge
Trial: 19576338
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers at admission only
Trial: 19576338
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers at discharge only
Trial: 19576338
Drug: No beta
RxNorm normalized name: Amidino beta-alanine
DrugBank: Ompenaclid (DB18819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta blockers at either point
Trial: 19576338
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers prescribed at discharge
Trial: 19576338
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of valsartan, captopril, and beta blockers
Trial: 15235821
Drug: Cremophor EL
RxNorm normalized name: cremophor el (polyethoxlated castor oil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cremophor EL (CrEL) 20 ml/m2 (equivalent to 175 mg/m2 paclitaxel)
Trial: 10841226
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ET results and TnT levels
Trial: 9398965
Drug: 1 mg‐kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg‐kg‐1 lidocaine
Trial: 9398965
Drug: 0.1 microgram‐1.kg‐1.min‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 microgram‐1.kg‐1.min‐1 PGE1 plus injection of 1 mg‐1.kg‐1 lidocaine
Trial: 23206319
Drug: AZD6765 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6765 (150 mg)
Trial: 21481253
Drug: MOVE! treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOVE! treatment plus PDA (PDA+)
Trial: 21481253
Drug: MOVE! treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOVE! treatment alone (Standard Care)
Trial: 19835582
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of GILP
Trial: 19835582
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of GILP
Trial: 9570600
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg epidural bupivacaine diluted in 4 mL (0.5%)
Trial: 9570600
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg epidural bupivacaine diluted in 10 mL (0.2%)
Trial: 9570600
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg epidural bupivacaine diluted in 20 mL (0.1%)
Trial: 21496343
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention consisting of three targeted pictorial messages regarding vaccines; administered by trained community health workers.
Trial: 16615955
Drug: Late provision
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late provision of parenteral amino acids (AA) (n = 836)
Trial: 16615955
Drug: Early provision
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early provision of parenteral amino acids (AA) (n = 182)
Trial: 11093966
Drug: Naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50 mg daily for 12 weeks
Trial: 26791025
Drug: Buccal and
RxNorm normalized name: Buprenorphine and Naloxone Buccal Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal and lingual infiltrations with 4% articaine and 1:100,000 adrenaline
Trial: 24030557
Drug: Brushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing with 1.0 g of Colgate Regular Flavor followed by applying 0.25 g of Tooth Mousse Plus (Group A)
Trial: 24030557
Drug: Brushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing with 1.0 g of Colgate Regular Flavor (Group C)
Trial: 20681273
Drug: Xuezhikang Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang Capsule (XZK) at a dose of 60 mg, twice a day, combined with hypotensive drugs
Trial: 20681273
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hypotensive drugs only)
Trial: 20681273
Drug: Xuezhikang Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang Capsule (XZK) combined with hypotensive drugs
Trial: 16298239
Drug: Insulin (induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (induced hyperinsulinemia)
Trial: 14616791
Drug: ALM mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALM mixed with low dose of BCG
Trial: 10810001
Drug: Lipase inhibitor
RxNorm normalized name: Lipase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipase inhibitor
Trial: 26755098
Drug: Ragweed SLIT
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragweed SLIT tablet (12 Ambrosia artemisiifolia 1-U) and grass SLIT tablet
Trial: 26507709
Drug: Timothy grass
RxNorm normalized name: Timothy grass
DrugBank: Phleum pratense top (DB14179)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timothy grass SLIT tablet
Trial: 26755098
Drug: Ragweed SLIT
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragweed SLIT tablet and grass SLIT tablet
Trial: 21095309
Drug: Glue or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glue or patch or buttressing
Trial: 12865592
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (2 mg/day) + norethisterone acetate (1 mg/day)
Trial: 12865592
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (0.05 mg) + norethisterone acetate (0.25 mg)
Trial: 19193505
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg/day)
Trial: 29027510
Drug: Topical hydroquinone
RxNorm normalized name: hydroquinone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hydroquinone (HQ) 2% applied once nightly for three months
Trial: 27209504
Drug: Sequential chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemoradiation therapy
Trial: 11530042
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment sequences